By the time a tumor reaches clinical detectability, it contains around 108–109 cells.
However, during tumor formation, significant cell loss occurs due to cell death. In some …

Heating Up IDH-Mutant Gliomas | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH The New England …

Targeting mitochondrial metabolic activity is an active area of cancer research. A study now
finds that a selective deficiency in mitochondrial complex I in melanoma cells increases …

Metabolic reprogramming in both immune and cancer cells plays a crucial role in the
antitumor immune response. Recent studies indicate that cancer metabolism not only …

Glioma evolution is governed by a multitude of dynamic interactions between tumor cells
and heterogenous neighboring, non-cancerous cells. This complex ecosystem, termed the …

Cholangiocarcinoma (CCA) is an aggressive bile duct malignancy with heterogeneous
genomic features. While most patients receive standard-of-care chemo/immunotherapy …

Human stem cell-derived models have emerged as an important platform to study tissue
differentiation and disease mechanisms. Those models could capitalize on biochemical and …

Isocitrate dehydrogenase 1 (IDH1) is a commonly mutated metabolic gene in cancer. Mutant
IDH1 produces the oncometabolite (R)-2-hydroxyglutarate (R-2HG), which inhibits histone …

New sequencing strategies have re-invigorated studies of the highly repetitive regions of the
genome, which were previously hidden from view. Emergence of numerous chromosome …

Mutations in isocitrate dehydrogenase (IDH) genes are among the most frequently
encountered molecular alterations in cholangiocarcinoma (CCA). These neomorphic point …